Literature DB >> 20388784

Mammalian target of rapamycin activator RHEB is frequently overexpressed in human carcinomas and is critical and sufficient for skin epithelial carcinogenesis.

Zhi Hong Lu1, Mark B Shvartsman, Andrew Y Lee, Jenny M Shao, Mollianne M Murray, Raleigh D Kladney, Dong Fan, Stan Krajewski, Gary G Chiang, Gordon B Mills, Jeffrey M Arbeit.   

Abstract

Small GTPase Ras homologue enriched in brain (RHEB) binds and activates the key metabolic regulator mTORC1, which has an important role in cancer cells, but the role of RHEB in cancer pathogenesis has not been shown. By performing a meta-analysis of published cancer cytogenetic and transcriptome databases, we defined a gain of chromosome 7q36.1-q36.3 containing the RHEB locus, an overexpression of RHEB mRNA in several different carcinoma histotypes, and an association between RHEB upregulation and poor prognosis in breast and head and neck cancers. To model gain of function in epithelial malignancy, we targeted Rheb expression to murine basal keratinocytes of transgenic mice at levels similar to those that occur in human squamous cancer cell lines. Juvenile transgenic epidermis displayed constitutive mTORC1 pathway activation, elevated cyclin D1 protein, and diffuse skin hyperplasia. Skin tumors subsequently developed with concomitant stromal angio-inflammatory foci, evidencing induction of an epidermal hypoxia-inducible factor-1 transcriptional program, and paracrine feed-forward activation of the interleukin-6-signal transducer and activator of transcription 3 pathway. Rheb-induced tumor persistence and neoplastic molecular alterations were mTORC1 dependent. Rheb markedly sensitized transgenic epidermis to squamous carcinoma induction following a single dose of Ras-activating carcinogen 7,12-dimethylbenz(a)anthracene. Our findings offer direct evidence that RHEB facilitates multistage carcinogenesis through induction of multiple oncogenic mechanisms, perhaps contributing to the poor prognosis of patients with cancers overexpressing RHEB. (c) 2010 AACR.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20388784      PMCID: PMC2855737          DOI: 10.1158/0008-5472.CAN-09-3467

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   12.701


  37 in total

Review 1.  Upstream and downstream of mTOR.

Authors:  Nissim Hay; Nahum Sonenberg
Journal:  Genes Dev       Date:  2004-08-15       Impact factor: 11.361

2.  TNM Classification of Malignant Tumors, fifth edition (1997). Union Internationale Contre le Cancer and the American Joint Committee on Cancer.

Authors:  L H Sobin; I D Fleming
Journal:  Cancer       Date:  1997-11-01       Impact factor: 6.860

3.  Serine phosphorylation and maximal activation of STAT3 during CNTF signaling is mediated by the rapamycin target mTOR.

Authors:  K Yokogami; S Wakisaka; J Avruch; S A Reeves
Journal:  Curr Biol       Date:  2000-01-13       Impact factor: 10.834

4.  Enhanced sensitivity of PTEN-deficient tumors to inhibition of FRAP/mTOR.

Authors:  M S Neshat; I K Mellinghoff; C Tran; B Stiles; G Thomas; R Petersen; P Frost; J J Gibbons; H Wu; C L Sawyers
Journal:  Proc Natl Acad Sci U S A       Date:  2001-08-14       Impact factor: 11.205

5.  Induction of hypervascularity without leakage or inflammation in transgenic mice overexpressing hypoxia-inducible factor-1alpha.

Authors:  D A Elson; G Thurston; L E Huang; D G Ginzinger; D M McDonald; R S Johnson; J M Arbeit
Journal:  Genes Dev       Date:  2001-10-01       Impact factor: 11.361

6.  Expression of Bcl-2 family member Bid in normal and malignant tissues.

Authors:  Maryla Krajewska; Juan M Zapata; Ivo Meinhold-Heerlein; Hirad Hedayat; Anne Monks; Herta Bettendorf; Ahmed Shabaik; Lukas Bubendorf; Olli-P Kallioniemi; Hoguen Kim; Guido Reifenberger; John C Reed; Stanislaw Krajewski
Journal:  Neoplasia       Date:  2002 Mar-Apr       Impact factor: 5.715

7.  Image analysis algorithms for immunohistochemical assessment of cell death events and fibrosis in tissue sections.

Authors:  Maryla Krajewska; Layton H Smith; Juan Rong; Xianshu Huang; Marc L Hyer; Nikolajs Zeps; Barry Iacopetta; Steven P Linke; Allen H Olson; John C Reed; Stan Krajewski
Journal:  J Histochem Cytochem       Date:  2009-03-16       Impact factor: 2.479

8.  Molecular classification of head and neck squamous cell carcinomas using patterns of gene expression.

Authors:  Christine H Chung; Joel S Parker; Gamze Karaca; Junyuan Wu; William K Funkhouser; Dominic Moore; Dale Butterfoss; Dong Xiang; Adam Zanation; Xiaoying Yin; William W Shockley; Mark C Weissler; Lynn G Dressler; Carol G Shores; Wendell G Yarbrough; Charles M Perou
Journal:  Cancer Cell       Date:  2004-05       Impact factor: 31.743

9.  Disruption of Stat3 reveals a critical role in both the initiation and the promotion stages of epithelial carcinogenesis.

Authors:  Keith Syson Chan; Shigetoshi Sano; Kaoru Kiguchi; Joanne Anders; Nobuyasu Komazawa; Junji Takeda; John DiGiovanni
Journal:  J Clin Invest       Date:  2004-09       Impact factor: 14.808

10.  mTOR inhibition reverses Akt-dependent prostate intraepithelial neoplasia through regulation of apoptotic and HIF-1-dependent pathways.

Authors:  Pradip K Majumder; Phillip G Febbo; Rachel Bikoff; Raanan Berger; Qi Xue; Louis M McMahon; Judith Manola; James Brugarolas; Timothy J McDonnell; Todd R Golub; Massimo Loda; Heidi A Lane; William R Sellers
Journal:  Nat Med       Date:  2004-05-23       Impact factor: 53.440

View more
  40 in total

Review 1.  mTOR in health and in sickness.

Authors:  Dritan Liko; Michael N Hall
Journal:  J Mol Med (Berl)       Date:  2015-09-22       Impact factor: 4.599

2.  Arl2-GTP and Arl3-GTP regulate a GDI-like transport system for farnesylated cargo.

Authors:  Shehab A Ismail; Yong-Xiang Chen; Alexandra Rusinova; Anchal Chandra; Martin Bierbaum; Lothar Gremer; Gemma Triola; Herbert Waldmann; Philippe I H Bastiaens; Alfred Wittinghofer
Journal:  Nat Chem Biol       Date:  2011-10-16       Impact factor: 15.040

3.  Hyperactivation of mammalian target of rapamycin complex 1 (mTORC1) promotes breast cancer progression through enhancing glucose starvation-induced autophagy and Akt signaling.

Authors:  Yongqiang Chen; Huijun Wei; Fei Liu; Jun-Lin Guan
Journal:  J Biol Chem       Date:  2013-11-25       Impact factor: 5.157

4.  ZEB1 sensitizes lung adenocarcinoma to metastasis suppression by PI3K antagonism.

Authors:  Yanan Yang; Young-Ho Ahn; Yulong Chen; Xiaochao Tan; Lixia Guo; Don L Gibbons; Christin Ungewiss; David H Peng; Xin Liu; Steven H Lin; Nishan Thilaganathan; Ignacio I Wistuba; Jaime Rodriguez-Canales; Georgia McLendon; Chad J Creighton; Jonathan M Kurie
Journal:  J Clin Invest       Date:  2014-04-24       Impact factor: 14.808

5.  Rapamycin is a potent inhibitor of skin tumor promotion by 12-O-tetradecanoylphorbol-13-acetate.

Authors:  L Allyson Checkley; Okkyung Rho; Tricia Moore; Steve Hursting; John DiGiovanni
Journal:  Cancer Prev Res (Phila)       Date:  2011-07

6.  Rapamycin and mTORC1 inhibition in the mouse: skin cancer prevention.

Authors:  Mohammad Athar; Levy Kopelovich
Journal:  Cancer Prev Res (Phila)       Date:  2011-07

Review 7.  Will targeting PI3K/Akt/mTOR signaling work in hematopoietic malignancies?

Authors:  Yanan Gao; Chase Y Yuan; Weiping Yuan
Journal:  Stem Cell Investig       Date:  2016-07-22

Review 8.  Recent progress in the study of the Rheb family GTPases.

Authors:  Jeffrey J Heard; Valerie Fong; S Zahra Bathaie; Fuyuhiko Tamanoi
Journal:  Cell Signal       Date:  2014-05-24       Impact factor: 4.315

9.  mTORC1 loss impairs epidermal adhesion via TGF-β/Rho kinase activation.

Authors:  Kaushal Asrani; Akshay Sood; Alba Torres; Dan Georgess; Pornima Phatak; Harsimar Kaur; Amber Dubin; C Conover Talbot; Loubna Elhelu; Andrew J Ewald; Bo Xiao; Paul Worley; Tamara L Lotan
Journal:  J Clin Invest       Date:  2017-09-25       Impact factor: 14.808

10.  Pten loss induces autocrine FGF signaling to promote skin tumorigenesis.

Authors:  Kristina Hertzler-Schaefer; Grinu Mathew; Ally-Khan Somani; Sunil Tholpady; Madhavi P Kadakia; Yiping Chen; Dan F Spandau; Xin Zhang
Journal:  Cell Rep       Date:  2014-02-27       Impact factor: 9.423

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.